Sevelamer - a drug for the treatment of hyperphosphatemia. Allilamine hydrochloride polymer, not absorbed in the gastrointestinal tract. The drug reduces the level of phosphorus in the blood, binding phosphates in the digestive tract, reduces their concentration in serum. It does not contain calcium and therefore does not cause hypercalcemia, observed against the background of other drugs that remove phosphates containing calcium.
treatment of hyperphosphatemia in patients on hemodialysis or peritonial dialysis;
to control hyperphosphatemia in patients with chronic kidney failure who are on dialysis with phosphorus greater than 1.78 mmol/l;
in complex therapy of control of renal osteodystrophy development for patients taking calcium and vitamin D3.
Vitamin D3 release form
Tablets coated with a film coating of 800 mg #180 in a container.
How to use
The required dosage and course of treatment is determined by a doctor based on the data on the concentration of phosphate in the blood.
The tablets should be swallowed in their entirety without being crushed, separated or chewed. The drug is prescribed in small doses, gradually increasing, every day (+1g) to the desired dose. The drug is taken regardless of the meal, drinking water. Blood control every 2-4 weeks.
When the concentration of phosphate in the blood from 1.78 - 2.42 mmol / l prescribe 1 tablet 3 times a day. At blood phosphate concentration above 2.42 mmol/l 2 tablets 3 times a day is prescribed. The average daily dose is 6 g. https://www.ncbi.nlm.nih.gov/pmc/?Db=pmc&Cmd=DetailsSearch&Term=Sevelamer
Contraindicated for children under 18 years old.
Use during pregnancy or lactation
Not recommended for use during pregnancy and lactation. If necessary, it is prescribed by a doctor, if the expected benefit for the mother exceeds the possible risk for the child.
Special features for use
The tablets contain lactose and are not recommended for patients with galactose intolerance, lactase deficiency or glucose-galactase malabsorption.
It is not recommended to take the drug in patients who have undergone organ transplantation, there may be a risk of rejection in case of drug incompatibility.